Skip to main content

Kenvue Inc. (KVUE) Stock

Kenvue Inc. Stock Details, Movements and Public Alerts

Kenvue (KVUE): The World's Largest Consumer Health Company Being Acquired by Kimberly-Clark for $48.7 Billion

Kenvue was spun off from Johnson & Johnson in 2023 as the world's largest pure-play consumer health company, owning household brands like Tylenol, Listerine, Neutrogena, Band-Aid, Aveeno, Benadryl, and Zyrtec. The company generates roughly $15 billion in annual revenue across three segments: Self Care, Skin Health and Beauty, and Essential Health. The stock's trajectory changed dramatically in 2025. CEO Thibaut Mongon was terminated in July, and interim CEO Kirk Perry began a strategic review. In November 2025, Kimberly-Clark announced the acquisition of Kenvue for $48.7 billion in total enterprise value, with the deal expected to close in H2 2026. The combined company would create a consumer products powerhouse spanning personal care, consumer health, and tissue products. Kenvue's brands hold leading market positions: Tylenol in OTC pain relief, Listerine in mouthwash, Neutrogena in skincare, and Band-Aid in wound care.

52-Week Range

$24.13 - $13.69

-26.56% from high · +29.44% from low

Avg Daily Volume

13,506,590

Latest volume

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

23.01

Near market average

Forward P/E

15.75

Earnings expected to grow

PEG Ratio

1.50

Reasonably valued

Price to Book

3.11

EV/EBITDA

13.78

EPS (TTM)

$0.76

Price to Sales

2.22

Beta

0.47

Less volatile than market

Q:How is KVUE valued relative to its earnings and growth?
Kenvue Inc. trades at a P/E ratio of 23.01, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 15.75 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 1.50 indicates reasonable value when growth is considered.
Q:What is KVUE's risk profile compared to the market?
With a beta of 0.47, Kenvue Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 3.11 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

9.72%

Operating Margin

17.80%

EBITDA

$3.24B

Return on Equity

14.40%

Return on Assets

6.61%

Revenue Growth (YoY)

3.20%

Earnings Growth (YoY)

11.20%

Q:How profitable and efficient is KVUE's business model?
Kenvue Inc. achieves a profit margin of 9.72%, meaning it retains $9.72 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 17.80% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 14.40% and ROA at 6.61%, the company achieves moderate returns on invested capital.
Q:What are KVUE's recent growth trends?
Kenvue Inc.'s revenue grew by 3.20% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 11.20% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against HOUSEHOLD & PERSONAL PRODUCTS industry averages for proper context.

Dividend Information

Dividend Per Share

$0.83

Dividend Yield

4.74%

Ex-Dividend Date

Feb 11, 2026

Dividend Date

Feb 25, 2026

Q:What dividend income can investors expect from KVUE?
Kenvue Inc. offers a dividend yield of 4.74%, paying $0.83 per share annually. This high yield exceeds 4%, significantly outperforming the S&P 500 average of 1.5-2% and most investment-grade bonds. For income-focused investors, this represents an attractive cash flow opportunity, though high yields sometimes signal market concerns about sustainability. To receive the next dividend, shares must be purchased before the ex-dividend date of Feb 11, 2026.
Q:How reliable is KVUE's dividend for long-term investors?
The dividend sustainability can be assessed through the payout ratio - Kenvue Inc. pays $0.83 per share in dividends against earnings of $0.76 per share, resulting in a payout ratio of 100.00%. This very high payout exceeding 90% raises sustainability concerns, as nearly all earnings go to dividends. Any earnings decline could force a dividend cut. The next dividend payment is scheduled for Feb 25, 2026.

Company Size & Market

Market Cap

$33.5B

Revenue (TTM)

$15.12B

Revenue/Share (TTM)

$7.89

Shares Outstanding

1.92B

Book Value/Share

$5.62

Asset Type

Common Stock

Q:What is KVUE's market capitalization and position?
Kenvue Inc. has a market capitalization of $33.5B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 1.92B shares outstanding, the company's ownership is widely distributed. As a participant in the HOUSEHOLD & PERSONAL PRODUCTS industry, it competes with other firms in this sector.
Q:How does KVUE's price compare to its book value?
Kenvue Inc.'s book value per share is $5.62, while the current stock price is $17.72, resulting in a price-to-book (P/B) ratio of 3.15. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$19.83

11.91% upside potential

Analyst Recommendations

Strong Buy

1

Buy

1

Hold

10

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for KVUE?
12 analysts cover KVUE with 17% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The bearish sentiment could create opportunity if analysts are wrong. The consensus target of $19.83 implies 11.9% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on KVUE?
Current analyst recommendations:1 Strong Buy, 1 Buy, 10 Hold, 00The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Mar 15, 2026, 02:32 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for KVUE and get notified when the price changes.

Kenvue (KVUE) Stock Analysis 2025: Complete Investment Guide

Household Brands Spanning Medicine Cabinets and Bathrooms

Kenvue's portfolio reads like a tour of the average American medicine cabinet. Tylenol and Motrin dominate OTC pain relief. Benadryl and Zyrtec lead in allergy treatment. Listerine is the top-selling mouthwash globally. Neutrogena and Aveeno are leading skincare brands. Band-Aid is so dominant in wound care that the brand name is used generically. Johnson's baby products have multi-generational recognition.

These brands share a common trait: strong consumer loyalty and repeat purchase behavior. A consumer who buys Tylenol for headaches does not typically switch to a generic alternative. This brand loyalty creates pricing power and stable revenue streams, even during economic downturns. Consumer health products are purchased regardless of recession or boom, making Kenvue's revenue base among the most defensive in consumer goods.

The Kimberly-Clark Acquisition

Kimberly-Clark announced the acquisition of Kenvue for $48.7 billion in total enterprise value in November 2025. The deal combines Kimberly-Clark's tissue and personal care brands (Huggies, Kleenex, Scott, Cottonelle) with Kenvue's consumer health portfolio. The combined company would have significant global distribution power, overlapping retail relationships, and complementary product categories.

The acquisition followed a turbulent period for Kenvue. CEO Thibaut Mongon was terminated in July 2025, and interim CEO Kirk Perry initiated a strategic review that ultimately led to the sale. The deal is expected to close in the second half of 2026, subject to regulatory approvals. For current shareholders, the acquisition price represents a premium to pre-announcement trading levels and provides certainty on exit value.

Financial Performance

  • •Trailing 12-Month Revenue: $15.0 billion, down 2.9% year-over-year
  • •FY2025 Guidance: Net sales change -1% to +1%; organic growth +2% to +4%
  • •Three Segments: Self Care (Tylenol, Benadryl, Zyrtec), Skin Health & Beauty (Neutrogena, Aveeno), Essential Health (Listerine, Band-Aid, Johnson's)
  • •Fortune 500: Debuted on the Fortune 500 list in 2025
  • •Acquisition Price: $48.7 billion total enterprise value from Kimberly-Clark
  • •Deal Timeline: Expected close H2 2026, subject to regulatory approvals

Growth Catalysts

  • •Acquisition Premium: Kimberly-Clark's $48.7B offer provides valuation certainty; spread to deal price offers potential return as regulatory approval progresses
  • •Emerging Market Growth: Consumer health penetration in developing markets remains below Western levels; Kenvue brands have global recognition that supports international expansion
  • •Self-Care Trend: Post-pandemic consumer awareness of health and wellness drives demand for OTC medications, skincare, and preventive health products
  • •Pricing Power: Branded consumer health products command premiums over generics; annual price increases contribute to organic revenue growth
  • •Combined Company Synergies: Kimberly-Clark expects cost savings from shared distribution, procurement, and back-office functions

Risks and Challenges

  • •Deal Completion Risk: Regulatory approvals required across multiple jurisdictions; antitrust concerns in specific product categories could force divestitures or block the deal
  • •Revenue Stagnation: Organic growth of 2-4% reflects a mature portfolio; several brands face private-label competition that limits share gains
  • •Tylenol Litigation: Ongoing lawsuits alleging links between acetaminophen use during pregnancy and neurodevelopmental disorders create contingent liability
  • •Skin Health Underperformance: Neutrogena and Aveeno have lost share to emerging DTC brands and Korean beauty products; revitalizing these brands requires significant marketing investment
  • •Post-Separation Challenges: Operating independently from J&J's infrastructure revealed higher standalone costs; the CEO termination suggests execution was not meeting board expectations

Competitive Landscape

In consumer health, Kenvue competes with Haleon (GSK's consumer health spinoff, brands include Advil, Sensodyne, Centrum), Reckitt Benckiser (Mucinex, Durex, Lysol), Procter & Gamble (Vicks, Pepto-Bismol), and Bayer Consumer Health (Aspirin, Claritin). Haleon is the closest pure-play competitor, also spun off from a pharmaceutical parent with a comparable revenue base.

In skincare, Neutrogena and Aveeno compete with L'Oreal (CeraVe, La Roche-Posay), Estee Lauder, and an expanding group of DTC and Korean beauty brands that have captured younger consumers. The skincare market is more fragmented and fashion-driven than OTC health, making market share harder to defend. Under Kimberly-Clark ownership, the combined company's distribution strength could help Kenvue's beauty brands compete more effectively for retail shelf space.

Who Is This Stock Suitable For?

Perfect For

  • ✓Merger arbitrage investors seeking to capture the spread between current price and the Kimberly-Clark acquisition price
  • ✓Defensive investors who want exposure to recession-resistant consumer health brands while the deal is pending
  • ✓Income investors collecting Kenvue's dividend while awaiting deal closure
  • ✓Those who believe the deal will close and want to own the combined Kimberly-Clark/Kenvue entity post-merger

Less Suitable For

  • ✗Growth investors (2-4% organic growth in a mature consumer health portfolio)
  • ✗Those concerned about deal break risk from regulatory challenges or antitrust issues
  • ✗Investors uncomfortable with the uncertainty of CEO transition and strategic direction changes
  • ✗Those seeking pure consumer health exposure that will no longer exist as a standalone company post-acquisition

Investment Thesis

Kenvue owns some of the most recognized consumer health brands in the world, generating $15 billion in annual revenue from products that consumers buy repeatedly. The Kimberly-Clark acquisition at $48.7 billion provides a defined exit for shareholders, with the deal expected to close in H2 2026. The primary investment consideration is now merger arbitrage: the spread between the current stock price and the deal price, adjusted for time to close and deal completion probability.

If the deal does not close, Kenvue would need a new permanent CEO, a refreshed growth strategy, and a plan to revitalize underperforming brands like Neutrogena. The brands themselves are durable assets, but the 2025 management turmoil and revenue stagnation showed that brand strength alone does not guarantee strong execution. For most investors, the Kimberly-Clark deal defines the near-term investment case: buy for the spread if you believe regulatory approval will proceed smoothly, or avoid if you see deal risk.

Conclusion

Kenvue is a pending acquisition target with iconic consumer health brands. The investment case centers on the Kimberly-Clark deal closing at the announced $48.7B enterprise value. The stock suits merger arbitrage investors and defensive holders who believe the deal will close. Long-term investors should evaluate whether they want exposure to the combined Kimberly-Clark/Kenvue entity.
Bull Case
$24 (30% upside) - Deal closes at full price with no material divestitures, spread captured, potential for upward price adjustment
Base Case
$20 (8% upside) - Deal closes in H2 2026 at announced terms, modest spread return accounting for time value
Bear Case
$14 (25% downside) - Deal blocked or renegotiated at lower price, standalone company faces CEO search and brand revitalization challenges

Stay Ahead of the Market with Kenvue Inc. Alerts

Set up price alerts for Kenvue Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.